Abstract
Psoriasis is a multifactorial chronic inflammatory skin disease of unknown etiology. Knowledge of the pathophysiology of psoriasis has evolved and identified IL-17 as a key pro-inflammatory mediator in psoriasis creating new medical avenues. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of moderate-to-severe psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. The currently available Phase I to III data indicate that ixekizumab is a well-tolerated promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.
| Original language | English |
|---|---|
| Journal | Immunotherapy |
| Volume | 7 |
| Issue number | 9 |
| Pages (from-to) | 957-66 |
| Number of pages | 10 |
| ISSN | 1750-743X |
| DOIs | |
| Publication status | Published - Sept 2015 |